{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T11:23:59Z","timestamp":1777893839967,"version":"3.51.4"},"reference-count":67,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100004325","name":"AstraZeneca","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004325","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100002491","name":"Bristol-Myers Squibb","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002491","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004328","name":"Genentech","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004328","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","thoracic.theclinics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Thoracic Surgery Clinics"],"published-print":{"date-parts":[[2025,11]]},"DOI":"10.1016\/j.thorsurg.2025.07.008","type":"journal-article","created":{"date-parts":[[2025,8,21]],"date-time":"2025-08-21T02:36:46Z","timestamp":1755743806000},"page":"389-405","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Molecular Therapy and Targeted Treatment for Cancer (with Surgical Lenses)"],"prefix":"10.1016","volume":"35","author":[{"given":"Narjust","family":"Florez","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Arthi","family":"Sridhar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lauren","family":"Kiel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Angela","family":"Morabito","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rebekah","family":"Kaufman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Coral","family":"Olazagasti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.thorsurg.2025.07.008_bib1","first-page":"7","article-title":"Cancer statistics, 2021","volume":"71","author":"Siegel","year":"2021","journal-title":"CA Cancer J Clin"},{"issue":"10","key":"10.1016\/j.thorsurg.2025.07.008_bib2","doi-asserted-by":"crossref","first-page":"358","DOI":"10.21037\/atm-22-4444","article-title":"Developments in targeted therapy & immunotherapy\u2014how non-small cell lung cancer management will change in the next decade: a narrative review","volume":"11","author":"Li","year":"2023","journal-title":"Ann Transl Med"},{"key":"10.1016\/j.thorsurg.2025.07.008_bib3","article-title":"Deep-LC: a novel deep learning method of identifying non-small cell lung cancer-related genes","volume":"12","author":"Li","year":"2022","journal-title":"Front Oncol"},{"key":"10.1016\/j.thorsurg.2025.07.008_bib4","series-title":"Non-small cell lung cancer: epidemiology, risk factors, treatment, and survivorship, Mayo clinic proceedings","first-page":"584","author":"Molina","year":"2008"},{"key":"10.1016\/j.thorsurg.2025.07.008_bib5","article-title":"Targeted next-generation sequencing of 491 lung cancers in clinical practice: implications for future detection strategy and targeted therapy","volume":"10","author":"Liu","year":"2024","journal-title":"Heliyon"},{"key":"10.1016\/j.thorsurg.2025.07.008_bib6","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1186\/s40364-024-00566-0","article-title":"Oncogenic alterations in advanced NSCLC: a molecular super-highway","volume":"12","author":"Friedlaender","year":"2024","journal-title":"Biomark Res"},{"key":"10.1016\/j.thorsurg.2025.07.008_bib7","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2022.910117","article-title":"Genomic landscape of lung cancer in the young","volume":"12","author":"Ruiz","year":"2022","journal-title":"Front Oncol"},{"key":"10.1016\/j.thorsurg.2025.07.008_bib8","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1002\/ijc.33583","article-title":"The genomic landscape of young and old lung cancer patients highlights age-dependent mutation frequencies and clinical actionability in young patients","volume":"149","author":"Cai","year":"2021","journal-title":"Int J Cancer"},{"key":"10.1016\/j.thorsurg.2025.07.008_bib9","doi-asserted-by":"crossref","first-page":"3200","DOI":"10.3390\/cells11203200","article-title":"Biomarker-targeted therapies in non\u2013small cell lung cancer: current status and perspectives","volume":"11","author":"Guo","year":"2022","journal-title":"Cells"},{"key":"10.1016\/j.thorsurg.2025.07.008_bib10","doi-asserted-by":"crossref","first-page":"217","DOI":"10.5306\/wjco.v12.i4.217","article-title":"Oncogenic driver mutations in non-small cell lung cancer: past, present and future","volume":"12","author":"Chevallier","year":"2021","journal-title":"World J Clin Oncol"},{"key":"10.1016\/j.thorsurg.2025.07.008_bib11","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1186\/s12935-023-02990-y","article-title":"Recent advances in non-small cell lung cancer targeted therapy; an update review","volume":"23","author":"Araghi","year":"2023","journal-title":"Cancer Cell Int"},{"key":"10.1016\/j.thorsurg.2025.07.008_bib12","article-title":"Epidermal growth factor receptor (EGFR): a rising star in the era of precision medicine of lung cancer","volume":"8","author":"Liu","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.thorsurg.2025.07.008_bib13","doi-asserted-by":"crossref","first-page":"3909","DOI":"10.21037\/jtd.2018.07.61","article-title":"A consensus on the role of osimertinib in non-small cell lung cancer from the AME Lung Cancer Collaborative Group","volume":"10","author":"Jiang","year":"2018","journal-title":"J Thorac Dis"},{"key":"10.1016\/j.thorsurg.2025.07.008_bib14","doi-asserted-by":"crossref","first-page":"LBA5-LBA5","DOI":"10.1200\/JCO.2020.38.18_suppl.LBA5","article-title":"Osimertinib as adjuvant therapy in patients with stage IB-IIIA EGFR mutation positive NSCLC after complete tumor resection: ADAURA","volume":"38","author":"Herbst","year":"2020","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.thorsurg.2025.07.008_bib15","doi-asserted-by":"crossref","first-page":"1711","DOI":"10.1056\/NEJMoa2027071","article-title":"Osimertinib in resected EGFR-mutated non\u2013small-cell lung cancer","volume":"383","author":"Wu","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.thorsurg.2025.07.008_bib16","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1056\/NEJMoa2402614","article-title":"Osimertinib after chemoradiotherapy in stage III EGFR-mutated NSCLC","volume":"391","author":"Lu","year":"2024","journal-title":"N Engl J Med"},{"key":"10.1016\/j.thorsurg.2025.07.008_bib17","series-title":"Neoadjuvant (neoadj) osimertinib (osi)\u00b1chemotherapy (CT) vs CT alone in resectable (R) epidermal growth factor receptor-mutated (EGFRm) NSCLC: NeoADAURA","author":"Chaft","year":"2025"},{"key":"10.1016\/j.thorsurg.2025.07.008_bib18","doi-asserted-by":"crossref","first-page":"1265","DOI":"10.1056\/NEJMoa2310532","article-title":"Alectinib in resected ALK-positive non\u2013small-cell lung cancer","volume":"390","author":"Wu","year":"2024","journal-title":"N Engl J Med"},{"key":"10.1016\/j.thorsurg.2025.07.008_bib19","unstructured":"Administration FaD: FDA approves alectinib as adjuvant treatment for ALK-positive non-small cell lung cancer, 2024."},{"key":"10.1016\/j.thorsurg.2025.07.008_bib20","doi-asserted-by":"crossref","first-page":"321","DOI":"10.5858\/arpa.2017-0388-CP","volume":"142","author":"Lindeman","year":"2018","journal-title":"Arch Pathol Lab Med"},{"key":"10.1016\/j.thorsurg.2025.07.008_bib21","doi-asserted-by":"crossref","first-page":"4585","DOI":"10.1158\/1078-0432.CCR-15-3101","article-title":"EGFR mutations and ALK rearrangements are associated with low response rates to PD-1 pathway blockade in non-small cell lung cancer: a retrospective analysis","volume":"22","author":"Gainor","year":"2016","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.thorsurg.2025.07.008_bib22","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.jtho.2018.10.009","article-title":"A cautionary analysis of immunotherapy prior to targeted therapy","volume":"14","author":"McCoach","year":"2019","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.thorsurg.2025.07.008_bib23","doi-asserted-by":"crossref","first-page":"1138","DOI":"10.1016\/j.jtho.2018.03.035","article-title":"A phase II study of pembrolizumab in EGFR-mutant, PD-l1+, tyrosine kinase inhibitor na\u00efve patients with advanced NSCLC","volume":"13","author":"Lisberg","year":"2018","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.thorsurg.2025.07.008_bib24","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/j.jtho.2018.09.001","article-title":"Increased hepatotoxicity associated with sequential immune checkpoint inhibitor and crizotinib therapy in patients with non-small cell lung cancer","volume":"14","author":"Lin","year":"2019","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.thorsurg.2025.07.008_bib25","first-page":"817","article-title":"Electro-optical switching of liquid crystals of graphene oxide, Liquid Crystals with Nano and Microparticles","volume":"5","author":"Song","year":"2017","journal-title":"World Scientific"},{"issue":"7","key":"10.1016\/j.thorsurg.2025.07.008_bib26","doi-asserted-by":"crossref","first-page":"e286","DOI":"10.1016\/j.cllc.2024.04.013","article-title":"Brief report on global clinician practices in the first-line management of metastatic non-small cell lung cancer","volume":"25","author":"Sridhar","year":"2024","journal-title":"Clin Lung Cancer"},{"key":"10.1016\/j.thorsurg.2025.07.008_bib27","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1056\/NEJMoa2302983","article-title":"Perioperative pembrolizumab for early-stage non\u2013small-cell lung cancer","volume":"389","author":"Wakelee","year":"2023","journal-title":"N Engl J Med"},{"key":"10.1016\/j.thorsurg.2025.07.008_bib28","doi-asserted-by":"crossref","first-page":"1756","DOI":"10.1056\/NEJMoa2311926","article-title":"Perioperative nivolumab in resectable lung cancer","volume":"390","author":"Cascone","year":"2024","journal-title":"N Engl J Med"},{"key":"10.1016\/j.thorsurg.2025.07.008_bib29","doi-asserted-by":"crossref","first-page":"1672","DOI":"10.1056\/NEJMoa2304875","article-title":"Perioperative durvalumab for resectable non\u2013small-cell lung cancer","volume":"389","author":"Heymach","year":"2023","journal-title":"N Engl J Med"},{"key":"10.1016\/j.thorsurg.2025.07.008_bib30","doi-asserted-by":"crossref","DOI":"10.1016\/j.jtocrr.2021.100187","article-title":"Response to immune checkpoint inhibition as monotherapy or in combination with chemotherapy in metastatic ROS1-rearranged lung cancers","volume":"2","author":"Choudhury","year":"2021","journal-title":"JTO Clinical and Research Reports"},{"key":"10.1016\/j.thorsurg.2025.07.008_bib31","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1200\/PO.18.00386","article-title":"Immunophenotype and response to immunotherapy of RET-rearranged lung cancers","volume":"3","author":"Offin","year":"2019","journal-title":"JCO Precision Oncology"},{"key":"10.1016\/j.thorsurg.2025.07.008_bib32","unstructured":"Moretti SBVLR, Bellezza G, Metro ASFRG, et al, RET rearrangement as a predictor of unresponsiveness to immunotherapy in non-small cell lung cancer: report of two cases with review of the literature. 2020."},{"key":"10.1016\/j.thorsurg.2025.07.008_bib33","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1056\/NEJMoa1713137","article-title":"Osimertinib in untreated EGFR-mutated advanced non\u2013small-cell lung cancer","volume":"378","author":"Soria","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.thorsurg.2025.07.008_bib34","doi-asserted-by":"crossref","first-page":"1830","DOI":"10.1200\/JCO.22.02186","article-title":"Adjuvant osimertinib for resected EGFR-mutated stage IB-IIIA non\u2013small-cell lung cancer: updated results from the phase III randomized ADAURA trial","volume":"41","author":"Herbst","year":"2023","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.thorsurg.2025.07.008_bib35","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1056\/NEJMoa2304594","article-title":"Overall survival with osimertinib in resected EGFR-mutated NSCLC","volume":"389","author":"Investigators","year":"2023","journal-title":"N Engl J Med"},{"key":"10.1016\/j.thorsurg.2025.07.008_bib36","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1016\/j.cllc.2023.02.002","article-title":"Adjuvant osimertinib vs. Placebo in completely resected stage IA2\u2013IA3 EGFR-mutated NSCLC: ADAURA2","volume":"24","author":"Tsutani","year":"2023","journal-title":"Clin Lung Cancer"},{"key":"10.1016\/j.thorsurg.2025.07.008_bib37","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1016\/j.cllc.2023.09.005","article-title":"TARGET: a Phase II, Open-Label, Single-Arm Study of 5-year adjuvant osimertinib in completely resected EGFR-mutated stage II to IIIB NSCLC post complete surgical resection","volume":"25","author":"Soo","year":"2024","journal-title":"Clin Lung Cancer"},{"key":"10.1016\/j.thorsurg.2025.07.008_bib38","doi-asserted-by":"crossref","DOI":"10.1016\/j.jtho.2021.01.375","article-title":"P03. 02 Neoadjuvant osimertinib with\/without chemotherapy vs chemotherapy for EGFR mutated resectable NSCLC: NeoADAURA","volume":"16","author":"Tsuboi","year":"2021","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.thorsurg.2025.07.008_bib39","series-title":"A phase I-III platform study evaluating the safety and efficacy of multiple therapies in patients with biomarker-defined locally advanced, unresectable stage III non\u2013small-cell lung cancer (NSCLC)","author":"Paz-Ares","year":"2023"},{"key":"10.1016\/j.thorsurg.2025.07.008_bib40","doi-asserted-by":"crossref","first-page":"S297","DOI":"10.1016\/j.jtho.2023.09.511","article-title":"P2. 01-06 NAUTIKA1 study: preliminary efficacy and safety data with neoadjuvant alectinib in patients with stage IB-III ALK+ NSCLC","volume":"18","author":"Lee","year":"2023","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.thorsurg.2025.07.008_bib41","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.jtho.2024.10.001","article-title":"Consolidation ALK tyrosine kinase inhibitor in definitively treated unresectable stage III ALK+ NSCLC: can real-world data inform clinical decision in the absence of a LAURA-type designed trial?","volume":"20","author":"Arter","year":"2025","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.thorsurg.2025.07.008_bib42","article-title":"New horizons for resectable non-small cell lung cancer: updates in perioperative treatment","volume":"3","author":"Martin","year":"2024","journal-title":"HOPA"},{"key":"10.1016\/j.thorsurg.2025.07.008_bib43","doi-asserted-by":"crossref","first-page":"1839","DOI":"10.1056\/NEJMoa2309457","article-title":"First-line selpercatinib or chemotherapy and pembrolizumab in RET fusion\u2013positive NSCLC","volume":"389","author":"Zhou","year":"2023","journal-title":"N Engl J Med"},{"key":"10.1016\/j.thorsurg.2025.07.008_bib44","doi-asserted-by":"crossref","first-page":"3133","DOI":"10.2217\/fon-2022-0656","article-title":"LIBRETTO-432, a phase III study of adjuvant selpercatinib or placebo in stage IB-IIIA RET fusion-positive non-small-cell lung cancer","volume":"18","author":"Tsuboi","year":"2022","journal-title":"Future Oncol"},{"key":"10.1016\/j.thorsurg.2025.07.008_bib45","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1016\/j.cell.2015.03.030","article-title":"Immune checkpoint targeting in cancer therapy: toward combination strategies with curative potential","volume":"161","author":"Sharma","year":"2015","journal-title":"Cell"},{"key":"10.1016\/j.thorsurg.2025.07.008_bib46","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1016\/1074-7613(94)90071-X","article-title":"CTLA-4 can function as a negative regulator of T cell activation","volume":"1","author":"Walunas","year":"1994","journal-title":"Immunity"},{"key":"10.1016\/j.thorsurg.2025.07.008_bib47","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1084\/jem.182.2.459","article-title":"CD28 and CTLA-4 have opposing effects on the response of T cells to stimulation","volume":"182","author":"Krummel","year":"1995","journal-title":"J Exp Med"},{"key":"10.1016\/j.thorsurg.2025.07.008_bib48","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1038\/s41419-023-06389-5","article-title":"Mechanisms of immune checkpoint inhibitors: insights into the regulation of circular RNAS involved in cancer hallmarks","volume":"15","author":"Meng","year":"2024","journal-title":"Cell Death Dis"},{"key":"10.1016\/j.thorsurg.2025.07.008_bib49","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1038\/s41571-021-00552-7","article-title":"Enhancing immunotherapy in cancer by targeting emerging immunomodulatory pathways","volume":"19","author":"Kraehenbuehl","year":"2022","journal-title":"Nat Rev Clin Oncol"},{"key":"10.1016\/j.thorsurg.2025.07.008_bib50","doi-asserted-by":"crossref","first-page":"1012","DOI":"10.1016\/S0140-6736(16)31473-8","article-title":"New and emerging targeted treatments in advanced non-small-cell lung cancer","volume":"388","author":"Hirsch","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.thorsurg.2025.07.008_bib51","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/j.lungcan.2019.06.005","article-title":"Heterogeneity of PD-L1 expression in non-small cell lung cancer: implications for specimen sampling in predicting treatment response","volume":"134","author":"Haragan","year":"2019","journal-title":"Lung Cancer"},{"key":"10.1016\/j.thorsurg.2025.07.008_bib52","doi-asserted-by":"crossref","first-page":"2177","DOI":"10.1158\/1078-0432.CCR-15-2246","article-title":"Heterogeneity of programmed cell death ligand 1 expression in multifocal lung cancer","volume":"22","author":"Mansfield","year":"2016","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.thorsurg.2025.07.008_bib53","doi-asserted-by":"crossref","first-page":"1973","DOI":"10.1056\/NEJMoa2202170","article-title":"Neoadjuvant nivolumab plus chemotherapy in resectable lung cancer","volume":"386","author":"Forde","year":"2022","journal-title":"N Engl J Med"},{"key":"10.1016\/j.thorsurg.2025.07.008_bib54","doi-asserted-by":"crossref","first-page":"2394","DOI":"10.1158\/2159-8290.CD-23-0436","article-title":"Neoadjuvant durvalumab alone or combined with novel immuno-oncology agents in resectable lung cancer: the phase II NeoCOAST platform trial","volume":"13","author":"Cascone","year":"2023","journal-title":"Cancer Discov"},{"key":"10.1016\/j.thorsurg.2025.07.008_bib55","doi-asserted-by":"crossref","DOI":"10.1016\/j.ctrv.2024.102833","article-title":"Surgical and safety outcomes in patients with non-small cell lung cancer receiving neoadjuvant chemoimmunotherapy versus chemotherapy alone: a systematic review and meta-analysis","volume":"131","author":"Aburaki","year":"2024","journal-title":"Cancer Treat Rev"},{"key":"10.1016\/j.thorsurg.2025.07.008_bib56","unstructured":"Clinical Care Options L: Phase III AEGEAN: analysis of surgery-related outcomes with neoadjuvant durvalumab + CT followed by adjuvant durvalumab in resectable NSCLC clinical care options, 2023."},{"key":"10.1016\/j.thorsurg.2025.07.008_bib57","doi-asserted-by":"crossref","first-page":"1265","DOI":"10.1056\/NEJMoa2310532","article-title":"Alectinib in resected ALK-positive non\u2013small-cell lung cancer","volume":"390","author":"Wu","year":"2024","journal-title":"N Engl J Med"},{"key":"10.1016\/j.thorsurg.2025.07.008_bib58","doi-asserted-by":"crossref","first-page":"1711","DOI":"10.1056\/NEJMoa2027071","article-title":"Osimertinib in resected EGFR-mutated non-small-cell lung cancer","volume":"383","author":"Wu","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.thorsurg.2025.07.008_bib59","first-page":"125","article-title":"An overview of precision oncology basket and umbrella trials for clinicians","volume":"70","author":"Park","year":"2020","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.thorsurg.2025.07.008_bib60","unstructured":"Institute NC: Definition of umbrella trial - NCI Dictionary of Cancer Terms."},{"key":"10.1016\/j.thorsurg.2025.07.008_bib61","article-title":"Basket and umbrella trials: untapped opportunities in rare disease","volume":"21","author":"Newton","year":"2021","journal-title":"Clinical Trials Arena [Internet]"},{"key":"10.1016\/j.thorsurg.2025.07.008_bib62","doi-asserted-by":"crossref","first-page":"2660","DOI":"10.1200\/JCO.24.00731","article-title":"Efficacy and safety of taletrectinib in Chinese patients with ROS1+ non\u2013small cell lung cancer: the phase II TRUST-I study","volume":"42","author":"Li","year":"2024","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.thorsurg.2025.07.008_bib63","doi-asserted-by":"crossref","first-page":"1337","DOI":"10.1200\/JCO-24-01727","article-title":"HER2-selective tyrosine kinase inhibitor, zongertinib (BI 1810631), in patients with advanced\/metastatic solid tumors with HER2 alterations: a phase Ia dose-escalation study","volume":"43","author":"Heymach","year":"2025","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.thorsurg.2025.07.008_bib64","first-page":"1","article-title":"Perioperative durvalumab plus chemotherapy plus new agents for resectable non-small-cell lung cancer: the platform phase II NeoCOAST-2 trial","volume":"1-9","author":"Cascone","year":"2025","journal-title":"Nat Med"},{"key":"10.1016\/j.thorsurg.2025.07.008_bib65","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1093\/oncolo\/oyad125","article-title":"Neoadjuvant versus adjuvant systemic therapy for early-stage non-small cell lung cancer: the changing landscape due to immunotherapy","volume":"28","author":"John","year":"2023","journal-title":"Oncologist"},{"key":"10.1016\/j.thorsurg.2025.07.008_bib66","doi-asserted-by":"crossref","first-page":"938","DOI":"10.1200\/CCI.20.00089","article-title":"Clone wars: quantitatively understanding cancer drug resistance","volume":"4","author":"Yates","year":"2020","journal-title":"JCO Clinical Cancer Informatics"},{"key":"10.1016\/j.thorsurg.2025.07.008_bib67","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/j.cels.2024.01.011","article-title":"Clonal differences underlie variable responses to sequential and prolonged treatment","volume":"15","author":"Schaff","year":"2024","journal-title":"Cell Syst"}],"container-title":["Thoracic Surgery Clinics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1547412725000507?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1547412725000507?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T07:02:54Z","timestamp":1777618974000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1547412725000507"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11]]},"references-count":67,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025,11]]}},"alternative-id":["S1547412725000507"],"URL":"https:\/\/doi.org\/10.1016\/j.thorsurg.2025.07.008","relation":{},"ISSN":["1547-4127"],"issn-type":[{"value":"1547-4127","type":"print"}],"subject":[],"published":{"date-parts":[[2025,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Molecular Therapy and Targeted Treatment for Cancer (with Surgical Lenses)","name":"articletitle","label":"Article Title"},{"value":"Thoracic Surgery Clinics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.thorsurg.2025.07.008","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}